Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Epsolay in Papulopustular Rosacea
NCT03564145Phase 3Terminated
- Sponsor
- Sol-Gel Technologies
- Start
- Sep 2018
- Primary completion
- Nov 2019
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zilxi in papulopustular rosacea, sponsored by Sol-Gel Technologies. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) at 52 weeks. Started Sep 2018; status: terminated.
02
Drugs
zilxi
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03564145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564145.